Apr 28, 2022 / NTS GMT
Kari Krogstad - Medistim ASA - President & CEO
Good morning, everyone, and welcome to Medistim (technical difficulty) 2022 presentation. My name is Kari Krogstad. And together with the colleague, CFO Thomas Jakobsen, we will take you through the results from this quarter.
And we are going to follow our agenda starting with the highlights, and then Thomas will take us through the financial statements. And then we will go through some further comments on the business segments and also some comments with regarding implementing our strategy. So let's get started on the highlights. So I'm very pleased to being able to present that again we are presenting an all-time high sales quarter. So this is actually the fifth quarter in a row where Medistim is delivering a sales number above NOK100 million. And as we can see, reaching NOK116.1 million compared to the NOK102.6 million last year, a growth of 13.2%.
As we can see, we have a little bit of favorable currency here, but not much. And the growth is coming from where we want it to come from. As we can see, the imaging portfolio, so the combined
Q1 2022 Medistim ASA Earnings Call Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers